Conferences - Results from #220

ESMO 2021: CheckMate 9KD Cohort A2 Final Analysis: Nivolumab + Rucaparib for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) September 19, 2021

ESMO 2021: Phase 1b/2 Study of Sabizabulin (VERU-111), an Androgen Receptor Transport Disruptor, in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Failed an Androgen Receptor Targeting Agent September 19, 2021

ESMO 2021: A Discussion on the Role of Abiraterone in Combination with Docetaxel and the Role of Abiraterone in Combination with ADT September 19, 2021

ESMO 2021: A Phase 3 Trial with a 2x2 Factorial Design in Men with De Novo Metastatic Castration-Sensitive Prostate Cancer: Overall Survival with Abiraterone Acetate plus Prednisone in PEACE-1 September 19, 2021

ESMO 2021: Health-Related Quality of Life, Pain and Safety Outcomes in the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients with mCRPC September 19, 2021

ESMO 2021: Abiraterone Acetate plus Prednisolone with or Without Enzalutamide Added to Androgen Deprivation Therapy Compared to ADT Alone for Men with High-Risk Non-Metastatic Prostate Cancer September 19, 2021

ESMO 2021: Darolutamide Maintenance in mCRPC Previously Treated with Novel Hormonal Agents and Non-Progressive Disease After Subsequent Treatment with a Taxane: A Randomized Double-Blind Placebo-Controlled Phase II Trial (SAKK 08/16) September 19, 2021

AIBCCR 2021: Bladder Cancer Metastasis September 19, 2021

ESMO 2021: STAR: A Randomized Multi-Stage Phase II/III Trial of Standard First-Line Therapy (Sunitinib or Pazopanib) Comparing Temporary Cessation with Allowing Continuation, in the Treatment of Locally Advanced And/or Metastatic RCC September 19, 2021

ESMO 2021: A Phase 3 Trial With a 2x2 Factorial Design in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer: Overall Survival With Abiraterone Acetate Plus Prednisone in PEACE-1 September 19, 2021

ESMO 2021: Pembrolizumab Versus Placebo as Adjuvant Therapy for Patients with RCC: Patient-Reported Outcomes in KEYNOTE-564 September 19, 2021

ESMO 2021: Single-Dose Carboplatin Followed by Involved-Node Radiotherapy As Curative Treatment for Seminoma Stage IIA/B: Efficacy Results From the International Multicenter Phase II Trial SAKK 01/10 September 19, 2021

ESMO 2021: Abiraterone Acetate Plus Prednisolone With or Without Enzalutamide Added to ADT Compared to ADT Alone for Men With High-Risk Non-Metastatic Prostate Cancer: Combined Analysis From Two Comparisons in the STAMPEDE Platform September 19, 2021

ESMO 2021: Pembrolizumab vs Placebo As Adjuvant Therapy for Patients With Renal Cell Carcinoma: Patient-Reported Outcomes in KEYNOTE-564 September 19, 2021

ESMO 2021: Nivolumab in Combination With Alternatively Scheduled Ipilimumab in First-Line Treatment of Patients With Advanced RCC: A Randomized Phase II Trial (PRISM) September 19, 2021

ESMO 2021: Subsequent Therapy Following Pembrolizumab + Axitinib or Sunitinib Treatment for Advanced RCC in the Phase 3 KEYNOTE-426 Study September 19, 2021

ESMO 2021: First-Line Nivolumab + Cabozantinib vs Sunitinib in Patients With Advanced RCC in Subgroups Based on Prior Nephrectomy in the CheckMate 9ER Trial September 19, 2021

ESMO 2021: Pembrolizumab Monotherapy As First-Line Therapy in Advanced Non–Clear Cell RCC: Results After a Minimum of 34 Months of Follow-Up From KEYNOTE-427 Cohort B September 19, 2021

ESMO 2021: Matching-Adjusted Indirect Comparison of Health-Related Quality of Life of Nivolumab plus Cabozantinib Versus Pembrolizumab plus Axitinib in Previously Untreated Advanced RCC September 19, 2021

ESMO 2021: Pembrolizumab Monotherapy as First-Line Therapy in Advanced Clear Cell RCC: Results After a Minimum of 41 Months of Follow-up From KEYNOTE-427 Cohort A September 19, 2021

Page 12 of 433

email news signup